• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum.

作者信息

Laird Mary E, Tong Lana X, Lo Sicco Kristen I, Kim Randie H, Meehan Shane A, Franks Andrew G

机构信息

Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York.

出版信息

JAAD Case Rep. 2017 Apr 14;3(3):228-229. doi: 10.1016/j.jdcr.2017.02.019. eCollection 2017 May.

DOI:10.1016/j.jdcr.2017.02.019
PMID:28443317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5394202/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df4a/5394202/13b1dbf55294/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df4a/5394202/13b1dbf55294/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df4a/5394202/13b1dbf55294/gr1.jpg

相似文献

1
Novel use of apremilast for adjunctive treatment of recalcitrant pyoderma gangrenosum.阿普司特用于顽固性坏疽性脓皮病辅助治疗的新用途。
JAAD Case Rep. 2017 Apr 14;3(3):228-229. doi: 10.1016/j.jdcr.2017.02.019. eCollection 2017 May.
2
Neutrophilic dermatoses: a review of current treatment options.嗜中性皮肤病：当前治疗选择综述
Am J Clin Dermatol. 2009;10(5):301-12. doi: 10.2165/11310730-000000000-00000.
3
Treatment of pyoderma gangrenosum with apremilast monotherapy.用阿普米司特单药疗法治疗坏疽性脓皮病。
JAAD Case Rep. 2022 Oct 11;30:8-10. doi: 10.1016/j.jdcr.2022.10.001. eCollection 2022 Dec.
4
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.与溃疡性结肠炎相关的泛发性坏疽性脓皮病：英夫利昔单抗和硫唑嘌呤治疗成功
Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5.
5
Refractory Pyoderma Gangrenosum: Stabilized on Colchicine and Tumor Necrosis Factor (TNF) Inhibitor.难治性坏疽性脓皮病：在秋水仙碱和肿瘤坏死因子（TNF）抑制剂治疗下病情稳定。
Cureus. 2022 Oct 18;14(10):e30419. doi: 10.7759/cureus.30419. eCollection 2022 Oct.
6
Recalcitrant cutaneous pyoderma gangrenosum with pulmonary involvement resolved with treatment of underlying plasma cell dyscrasia.伴有肺部受累的顽固性皮肤坏疽性脓皮病经潜在浆细胞发育异常的治疗后得以缓解。
JAAD Case Rep. 2021 Jan 12;9:28-30. doi: 10.1016/j.jdcr.2020.12.028. eCollection 2021 Mar.
7
What do autoinflammatory syndromes teach about common cutaneous diseases such as pyoderma gangrenosum? A commentary.自身炎症性疾病对常见皮肤疾病（如坏疽性脓皮病）有何启示？评论。
Dermatol Clin. 2013 Jul;31(3):427-35. doi: 10.1016/j.det.2013.04.004. Epub 2013 May 10.
8
Multiple Facial Lesions of Recalcitrant Pyoderma Gangrenosum Successfully Treated with Adalimumab.阿达木单抗成功治疗多发性顽固性坏疽性脓皮病面部病变
J Clin Aesthet Dermatol. 2019 May;12(5):28-32. Epub 2019 May 1.
9
Drug-induced pyoderma gangrenosum: a model to understand the pathogenesis of pyoderma gangrenosum.药物诱导性坏疽性脓皮病：一种理解坏疽性脓皮病发病机制的模型。
Br J Dermatol. 2017 Jul;177(1):72-83. doi: 10.1111/bjd.15193. Epub 2017 Jun 14.
10
[Deep-seated granulomatous pyoderma gangrenosum: A novel variant?].[深部肉芽肿性坏疽性脓皮病：一种新的变异型？]
Ann Dermatol Venereol. 2015 May;142(5):340-5. doi: 10.1016/j.annder.2014.11.010. Epub 2015 Jan 27.

引用本文的文献

1
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review.坏疽性脓皮病和化脓性汗腺炎的新治疗方法：综述。
J Dermatol. 2024 Feb;51(2):172-179. doi: 10.1111/1346-8138.17031. Epub 2023 Nov 27.
2
Treatment of pyoderma gangrenosum with apremilast monotherapy.用阿普米司特单药疗法治疗坏疽性脓皮病。
JAAD Case Rep. 2022 Oct 11;30:8-10. doi: 10.1016/j.jdcr.2022.10.001. eCollection 2022 Dec.
3
Atypical Forms of Pyoderma Gangrenosum in Inflammatory Bowel Disease: Report of Four Cases and Literature Review.炎症性肠病中坏疽性脓皮病的非典型形式：4例报告及文献综述

本文引用的文献

1
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).阿普米司特，一种口服磷酸二酯酶 4 抑制剂，治疗中重度斑块状银屑病患者的疗效和安全性：一项为期 52 周的 III 期随机对照试验（ESTEEM 2）。
Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7.
2
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).阿普米司特，一种口服磷酸二酯酶 4（PDE4）抑制剂，用于治疗中重度斑块状银屑病患者：一项 III 期、随机、对照试验（评估阿普米司特治疗银屑病的疗效和安全性试验 [ESTEEM] 1）的结果。
J Am Acad Dermatol. 2015 Jul;73(1):37-49. doi: 10.1016/j.jaad.2015.03.049.
3
Int Med Case Rep J. 2022 Aug 26;15:449-456. doi: 10.2147/IMCRJ.S376915. eCollection 2022.
4
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.坏疽性脓皮病：已确立和新兴药物治疗的最新文献综述。
Am J Clin Dermatol. 2022 Sep;23(5):615-634. doi: 10.1007/s40257-022-00699-8. Epub 2022 May 24.
5
What is new in dermatotherapy?皮肤科治疗领域有哪些新进展？
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):135-143. doi: 10.25259/IJDVL_342_20.
6
Skin manifestations in spondyloarthritis.脊柱关节炎的皮肤表现
Ther Adv Musculoskelet Dis. 2020 Dec 8;12:1759720X20975915. doi: 10.1177/1759720X20975915. eCollection 2020.
7
Pyoderma gangrenosum.坏疽性脓皮病。
Nat Rev Dis Primers. 2020 Oct 8;6(1):81. doi: 10.1038/s41572-020-0213-x.
8
Recent advances in managing and understanding pyoderma gangrenosum.坏疽性脓皮病管理与认识的最新进展
F1000Res. 2019 Dec 12;8. doi: 10.12688/f1000research.19909.1. eCollection 2019.
9
Multiple Facial Lesions of Recalcitrant Pyoderma Gangrenosum Successfully Treated with Adalimumab.阿达木单抗成功治疗多发性顽固性坏疽性脓皮病面部病变
J Clin Aesthet Dermatol. 2019 May;12(5):28-32. Epub 2019 May 1.
10
Pyoderma gangrenosum controlled with rituximab.利妥昔单抗控制坏疽性脓皮病。
JAAD Case Rep. 2019 Jun 26;5(7):593-595. doi: 10.1016/j.jdcr.2019.04.019. eCollection 2019 Jul.
Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.阿普米司特治疗白塞综合征的 2 期、安慰剂对照研究。
N Engl J Med. 2015 Apr 16;372(16):1510-8. doi: 10.1056/NEJMoa1408684.
4
Vegetative pyoderma gangrenosum.增殖性坏疽性脓皮病
Dermatol Online J. 2014 Dec 16;20(12):13030/qt6x3826zq.
5
Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.两种典型自身炎症性皮肤病——坏疽性脓皮病和Sweet综合征中细胞因子、趋化因子及其他效应分子的表达
Clin Exp Immunol. 2014 Oct;178(1):48-56. doi: 10.1111/cei.12394.
6
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.阿普司特治疗盘状红斑狼疮：一项2期开放标签单臂试验研究结果
J Drugs Dermatol. 2012 Oct;11(10):1224-6.
7
Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.阿普米司特：一种新型 PDE4 抑制剂，用于治疗自身免疫性和炎症性疾病。
Ther Adv Musculoskelet Dis. 2010 Oct;2(5):271-8. doi: 10.1177/1759720X10381432.
8
Etiology and management of pyoderma gangrenosum: a comprehensive review.坏疽性脓皮病的病因和治疗：全面综述。
Am J Clin Dermatol. 2012 Jun 1;13(3):191-211. doi: 10.2165/11595240-000000000-00000.
9
Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum.浅表性肉芽肿性脓皮病：坏疽性脓皮病的一种局限性增殖型。
J Am Acad Dermatol. 1988 Mar;18(3):511-21. doi: 10.1016/s0190-9622(88)70074-2.